Sarepta Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 215 FIRST STREET, CAMBRIDGE, MA, 02142
Mailing Address 215 FIRST STREET, CAMBRIDGE, MA, 02142
Phone 617-274-4000
Fiscal Year End 1231
EIN 930797222
Financial Overview
FY2024
$2.44B
Total Liabilities
$1.53B
Stockholders' Equity
$1.10B
Cash & Equivalents
$2.47
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 13, 2026 | View on SEC |
| 13F-HR Institutional investment holdings | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | January 29, 2026 | View on SEC |
| 4 Insider stock transaction report | January 29, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 21, 2026 | View on SEC |
| 8-K Current report of material events | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 8-K Current report of material events | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
| 8-K Current report of material events | December 11, 2025 | View on SEC |
Insider Trading
SELL 1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.